Small Intestinal Submucosa Biomimetic Periosteum Promotes Bone Regeneration

Yanlin Su, Bing Ye, Lian Zeng, Zekang Xiong, Tingfang Sun, Kaifang Chen, Qiuyue Ding, Weijie Su, Xirui Jing, Qing Gao, Guixiong Huang, Yizhou Wan, Xu Yang, Xiaodong GuoMembranes 2022 · DOI

TL;DR

Researchers have developed a novel biomimetic periosteum using a core-shell electrospinning technique with decellularized porcine small intestinal submucosa (SIS) and polycaprolactone (PCL). This engineered material effectively promotes bone regeneration by mimicking the natural periosteum's structure and function, showing promise for treating critical bone defects.

What Problem Does This Paper Address?

Repairing large bone defects, often resulting from trauma, tumor removal, or congenital issues, remains a significant clinical challenge. Current gold-standard treatments like autografts and allografts have limitations, including limited availability, risk of disease transmission, and immune rejection. Tissue engineering offers a promising alternative, but existing engineered constructs often struggle with insufficient osteogenic efficiency and vascularization. The periosteum, a vital tissue for bone regeneration due to its rich vascular network and osteogenic cells, is a key target for biomimetic approaches. However, replicating its complex structure and function has been difficult. This paper aims to address this by creating a biomimetic periosteum that can effectively support vascularization and osteogenesis for improved bone defect repair.

Methods

The core innovation in this study is the fabrication of a biomimetic periosteum using coaxial electrospinning. This technique allowed for the creation of core-shell nanofibers where:

  • Shell: Decellularized porcine small intestinal submucosa (SIS) was used as the outer layer. SIS is a natural extracellular matrix (ECM) rich in bioactive factors and known for its biocompatibility.
  • Core: Polycaprolactone (PCL), a biocompatible and electrospinnable polymer, formed the inner core.

This approach aimed to preserve the biological activity of SIS while providing structural support and mechanical strength from PCL. The resulting fibers were arranged in a parallel, ordered manner, mimicking the natural periosteum's structure.

To evaluate the material's efficacy, the researchers employed a multi-pronged approach:

  • In Vitro Studies:
    • Cell Proliferation: EdU assays were used to assess the proliferation of Schwann cells (SCs), human umbilical vein endothelial cells (HUVECs), and bone marrow mesenchymal stem cells (BMSCs) when cultured with the biomimetic periosteum.
  • Cell Migration: Wound scratch assays were performed to evaluate the migration of SCs and HUVECs.
  • Angiogenesis: A tube formation assay using Matrigel was conducted to assess the ability of HUVECs to form vascular-like structures.
  • Osteogenesis: Alizarin Red staining was used to detect calcium nodule formation by BMSCs, indicating osteogenic differentiation. Quantitative RT-PCR was also used to measure the expression of key osteogenic genes (ALP, OCN, Runx2, Col1a1).
  • Immunofluorescence: Staining for markers like S100 and C-JUN was used to assess Schwann cell guidance and phenotypic transformation.
  • In Vivo Studies:
    • A rat cranial defect model was established.
  • The biomimetic periosteum (c-PCL/s-SIS) and a control PCL group were implanted into the defects.
  • After 8 weeks, histological analysis (H&E staining) was performed to evaluate bone regeneration and new bone formation.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • SIS as a Bioactive Shell: Using SIS as the shell in a core-shell electrospun structure effectively preserves its inherent bioactivity while providing a scaffold for cell interaction and growth.
  • Mimicking Periosteal Structure: The ordered, parallel arrangement of the core-shell fibers successfully mimics the structural cues of the natural periosteum, guiding cell behavior.
  • Synergistic Effects: The combination of SIS and PCL in a core-shell structure appears to create a synergistic effect, promoting not only osteogenesis but also crucial angiogenesis and Schwann cell activity, which are all vital for effective bone regeneration.
  • Dual Role of Schwann Cells: The study highlights the dual role of Schwann cells in promoting both vascularization and osteogenesis, suggesting their importance in the engineered periosteum's function.
  • FDA-Approved PCL Advantage: The use of PCL, an FDA-approved material, potentially streamlines the path towards clinical translation.

Key Results

  • In Vitro:
    • The c-PCL/s-SIS biomimetic periosteum significantly enhanced the proliferation of HUVECs (3.03 times) and SCs (6.96 times) compared to the PCL group.
  • It promoted HUVEC migration, leading to wound healing one day earlier than the PCL group.
  • Angiogenesis was significantly promoted, with the c-PCL/s-SIS group showing over 10 times more tube formation than the PCL group.
  • BMSC proliferation was significantly increased (7.53 times) with the c-PCL/s-SIS group.
  • Osteogenic differentiation of BMSCs was significantly enhanced, with Alizarin Red staining showing a 2.53-fold increase and upregulation of key osteogenic genes (ALP, OCN, Runx2, Col1a1) by 1.86 to 3.45 times.
  • Schwann cells showed enhanced guidance and phenotypic transformation (C-JUN expression increased 2.05 times) on the c-PCL/s-SIS.
  • In Vivo:
    • Histological analysis at 8 weeks showed significantly greater collagen deposition and newly formed bone area in the c-PCL/s-SIS group compared to the PCL group, indicating superior bone defect repair.

Limitations and Future Work

  • Animal Model: While the rat cranial defect model is relevant, future studies could explore larger animal models to further validate the efficacy and safety of the biomimetic periosteum.
  • Long-Term Efficacy: The study focused on 8-week outcomes. Longer-term studies would be beneficial to assess the durability and complete integration of the regenerated bone.
  • Immunogenicity: While SIS is generally considered to have low immunogenicity, further detailed immunological assessments in a clinical context might be warranted.
  • Clinical Translation: The authors suggest this strategy provides a promising method for clinical treatment, implying that further pre-clinical and clinical trials are the logical next steps. The use of FDA-approved PCL is a positive step towards this.

Summary updated

Abstract

The biomimetic periosteum could simulate the structural function of the periosteum and promote bone repair. This strategy may provide a promising method for the clinical treatment of skull bone defects.
BibTeX
@inproceedings{su2022small,
  author = {Yanlin Su and Bing Ye and Lian Zeng and Zekang Xiong and Tingfang Sun and Kaifang Chen and Qiuyue Ding and Weijie Su and Xirui Jing and Qing Gao and Guixiong Huang and Yizhou Wan and Xu Yang and Xiaodong Guo},
  title = {{Small Intestinal Submucosa Biomimetic Periosteum Promotes Bone Regeneration}},
  booktitle = {Membranes},
  year = {2022},
  doi = {10.3390/membranes12070719},
}
Figure